Accelerate Diagnostics, the Tucson-based company specializing in medical diagnostics, has battled against financial headwinds long enough to eventually give in and file for Chapter 11 bankruptcy. This news emerges alongside the company's push for an asset sale, as reported on Monday. According to ABC15, the petition was filed on May 8th in the U.S. Bankruptcy Court for the District of Delaware, setting the stage for an authorized auction or sale of its assets.
In the throes of restructuring, Accelerate Diagnostics has not only filed for bankruptcy but has also commenced with its asset sale process. Per the details from Investing.com, the company struck a deal with Indaba Capital Management, which agreed to purchase substantially all of Accelerate's assets, infusing some hope to obtain debtor-in-possession financing up to $12.5 million for the company's continued operations.
Documents made available by the Bankruptcy Court online reflect an open transparency into the company’s ongoing efforts to steady the ship through the rough financial waters it has found itself in. First day motions filed by Accelerate Diagnostics include measures to ensure the company can maintain its operations, notably obtaining approval to pay employees their due wages and benefits.
With a commitment from Indaba Capital that includes a $36.9 million credit bid against secured notes and additional financial boost through debtor-in-possession financing, the company stands at a critical juncture, awaiting higher bids in a court-overseen auction. Legal counsel for the case has been identified as Fried, Frank, Harris, Shriver & Jacobson LLP, and supported by advisory and banking expertise from Solic Capital and Perella Weinberg Partners L.P., respectively, as pinpointed by Investing.com.
Despite the bankruptcy backdrop, Accelerate Diagnostics has not put the brakes on innovation. The company is cruising forward with the submission of its Accelerate WAVE™ system for FDA clearance. Following the expansion of its board by including two new independent directors and approving retention bonuses for top executives, the company aims to secure leadership while navigating through these financial straits. These decisions coincide with the formation of a Special Committee, focused on exploring strategic options to maximize value, as mentioned by Investing.com.
For investors keeping an eye on the unfolding scenario, the question remains whether Accelerate Diagnostics represents a wise investment at this stage. Investing.com suggests that with its sophisticated AI algorithms, AXDX, along with other undervalued stocks, could offer substantial returns as the market rights itself from its current imbalance. However, investors are advised to stay tuned and watch the market dynamics closely following Accelerate's bold moves amidst their Chapter 11 announcement.
